CAR T cells show activity
Nature Reviews Clinical Oncology, Published online: 23 May 2022; doi:10.1038/s41571-022-00648-8CAR T cells show activity (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 23, 2022 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Ensuring completeness and timeliness of cancer treatment guidelines
Nature Reviews Clinical Oncology, Published online: 20 May 2022; doi:10.1038/s41571-022-00646-wTimely and comprehensive updating of treatment guidelines remains a challenge and necessity in medical oncology. Herein we discuss our assessment of how trial results with four off-patent drugs have been considered for integration into major guidelines in the absence of a commercial sponsor, in which we found reasons for concern. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 20, 2022 Category: Cancer & Oncology Authors: Gauthier Bouche Lydie Meheus Source Type: research
Role of neoadjuvant chemoimmunotherapy for resectable NSCLC
Nature Reviews Clinical Oncology, Published online: 18 May 2022; doi:10.1038/s41571-022-00647-9Immune-checkpoint inhibitors have revolutionized the treatment of patients with non-small-cell lung cancer (NSCLC). Recently, indications for immune-checkpoint inhibitors have expanded from advanced-stage NSCLC to adjuvant, and now neoadjuvant, therapy for resectable NSCLC, with three cycles of preoperative chemoimmunotherapy achieving superior pathological complete response rates and event-free survival compared with chemotherapy alone in the phase III CheckMate 816 trial. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 18, 2022 Category: Cancer & Oncology Authors: Boris Sepesi Stephen G. Swisher Source Type: research
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Nature Reviews Clinical Oncology, Published online: 09 May 2022; doi:10.1038/s41571-022-00639-9Patients with non-small-cell lung cancers (NSCLCs) harbouring oncogenic EGFR or ALK alterations can benefit from therapies targeting these alterations, although acquired resistance to these agents is common. Third-generation inhibitors have extended the response durations of many patients with NSCLCs harbouring these alterations, albeit with differing patterns of resistance to those associated with earlier-generation agents. Here, the authors describe the mechanisms of acquired resistance to third-generation EGFR and ALK inhibito...
Source: Nature Reviews Clinical Oncology - May 9, 2022 Category: Cancer & Oncology Authors: Alissa J. Cooper Lecia V. Sequist Jessica J. Lin Source Type: research
Ivosidenib combination improves OS
Nature Reviews Clinical Oncology, Published online: 09 May 2022; doi:10.1038/s41571-022-00644-yIvosidenib combination improves OS (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 9, 2022 Category: Cancer & Oncology Authors: David Killock Source Type: research
From AACR 2022
Nature Reviews Clinical Oncology, Published online: 03 May 2022; doi:10.1038/s41571-022-00642-0From AACR 2022 (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 3, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Response to neoadjuvant endocrine therapy complements recurrence score
Nature Reviews Clinical Oncology, Published online: 29 April 2022; doi:10.1038/s41571-022-00641-1Response to neoadjuvant endocrine therapy complements recurrence score (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 29, 2022 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
An appraisal of FDA approvals for adult solid tumours in 2017–2021: has the eagle landed?
Nature Reviews Clinical Oncology, Published online: 28 April 2022; doi:10.1038/s41571-022-00636-yIn this Perspective, Nathan Cherny appraises the FDA approvals of therapeutic agents granted for use in adult patients with solid tumours during the 5 years 2017–2021 against the aspirations of the Cancer Moonshot, in terms of sheer number of approvals, the strength of the supporting evidence and the magnitude of clinical benefit. He also outlines areas where improvements are needed to more confidently ensure that the clinical benefits of approved treatments justify the associated risks. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 28, 2022 Category: Cancer & Oncology Authors: Nathan I. Cherny Source Type: research
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
Nature Reviews Clinical Oncology, Published online: 28 April 2022; doi:10.1038/s41571-022-00633-1Several PI3K pathway inhibitors are currently approved as cancer treatments; however, finding an acceptable therapeutic window to target this key signalling cascade linking cancer growth with metabolism has proven challenging and the clinical results to date have arguably been disappointing. In this Review, Vasan and Cantley discuss the effects of PI3K pathway alterations on signalling and metabolism in solid tumours as well as past and present efforts to improve the somewhat limited clinical efficacy of PI3K pathway inhibitors...
Source: Nature Reviews Clinical Oncology - April 28, 2022 Category: Cancer & Oncology Authors: Neil Vasan Lewis C. Cantley Source Type: research
Prospective insights on the use of bTMB
Nature Reviews Clinical Oncology, Published online: 27 April 2022; doi:10.1038/s41571-022-00640-2Prospective insights on the use of bTMB (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 27, 2022 Category: Cancer & Oncology Authors: David Killock Source Type: research
Optimal systemic therapy for high-risk resectable melanoma
Nature Reviews Clinical Oncology, Published online: 25 April 2022; doi:10.1038/s41571-022-00630-4Immune-checkpoint inhibitors and BRAF-targeted therapy have revolutionized the treatment of advanced-stage, unresectable melanoma and have been successfully transitioned into the resectable disease setting as (neo)adjuvant treatments. The expanding range of treatment options available for resectable high-risk melanoma raises questions over selection of the optimal therapeutic strategy and agents for each individual. Furthermore, the use of perioperative therapy has potentially important implications for the management of patien...
Source: Nature Reviews Clinical Oncology - April 25, 2022 Category: Cancer & Oncology Authors: Alexander M. M. Eggermont Omid Hamid Georgia V. Long Jason J. Luke Source Type: research
Gut microbes as biomarkers of ICI response — sharpening the focus
Nature Reviews Clinical Oncology, Published online: 21 April 2022; doi:10.1038/s41571-022-00634-0Two recent large-cohort studies reinforce the potential predictive capability of gut microbiota for immune-checkpoint inhibitor response and toxicities in patients with melanoma. However, additional investigations are required to understand the mechanistic underpinnings of this complex multifaceted relationship, and how it can be exploited for personalized cancer care. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 21, 2022 Category: Cancer & Oncology Authors: Neal Bhutiani Jennifer A. Wargo Source Type: research
Integrated MRI-guided radiotherapy — opportunities and challenges
Nature Reviews Clinical Oncology, Published online: 19 April 2022; doi:10.1038/s41571-022-00631-3In the past decade, treatment devices that combine imaging with targeted irradiation have been developed to deliver MRI-guided radiotherapy (MRIgRT). This treatment modality uses motion management and biological targeting to improve local control rates whilst reducing the radiation delivered to non-malignant tissues. The authors of this Review describe the current state of MRIgRT, and the opportunities and challenges of this radiotherapy approach. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 19, 2022 Category: Cancer & Oncology Authors: Paul J. Keall Caterina Brighi Carri Glide-Hurst Gary Liney Paul Z. Y. Liu Suzanne Lydiard Chiara Paganelli Trang Pham Shanshan Shan Alison C. Tree Uulke A. van der Heide David E. J. Waddington Brendan Whelan Source Type: research
Pembrolizumab reduces recurrence risk in stage II melanoma
Nature Reviews Clinical Oncology, Published online: 19 April 2022; doi:10.1038/s41571-022-00638-wPembrolizumab reduces recurrence risk in stage II melanoma (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 19, 2022 Category: Cancer & Oncology Authors: David Killock Source Type: research
Combining CAR T cells effective in RRMM
Nature Reviews Clinical Oncology, Published online: 12 April 2022; doi:10.1038/s41571-022-00637-xCombining CAR T cells effective in RRMM (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 12, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
